We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

29 hedge funds and large institutions have $752K invested in Aevi Genomic Medicine Inc in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

4% more funds holding

Funds holding: 28 → 29 (+1)

6% less capital invested

Capital invested by funds: $803K → $752K (-$51K)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

Holders
29
Holders Change
+1
Holders Change %
+3.57%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$175K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$115K
3
AMCA
Arthur M. Cohen & Associates
Illinois
+$13K
4
TSS
Two Sigma Securities
New York
+$7.84K
5
OIA
OneDigital Investment Advisors
Kansas
+$3.15K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$46.9K
2
BCM
Bridgeway Capital Management
Texas
-$44K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$35.3K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$25K
5
BlackRock
BlackRock
New York
-$19.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$313K +$175K +863,474 +79%
Vanguard Group
2
Vanguard Group
Pennsylvania
$201K +$115K +566,497 +83%
BlackRock
3
BlackRock
New York
$109K -$19.6K -96,925 -12%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$26K – – –
BC
5
Birchview Capital
Vermont
$20K – – –
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$15K -$35.3K -174,600 -65%
AMCA
7
Arthur M. Cohen & Associates
Illinois
$10K +$13K +64,390 New
VF
8
Virtu Financial
New York
$8K -$46.9K -231,821 -83%
California Public Employees Retirement System
9
California Public Employees Retirement System
California
$8K – – –
Northern Trust
10
Northern Trust
Illinois
$8K – – –
UBS Group
11
UBS Group
Switzerland
$7K -$6.56K -32,396 -42%
TSS
12
Two Sigma Securities
New York
$6K +$7.84K +38,726 New
OIA
13
OneDigital Investment Advisors
Kansas
$4K +$3.15K +15,555 +100%
State Street
14
State Street
Massachusetts
$3K – – –
VAM
15
Verity Asset Management
North Carolina
$3K – – –
Citadel Advisors
16
Citadel Advisors
Florida
$2K -$10.5K -51,671 -78%
MWP
17
MYCIO Wealth Partners
Pennsylvania
$2K – – –
Wells Fargo
18
Wells Fargo
California
$2K – – –
DAS
19
Dynamic Advisor Solutions
Arizona
$2K +$2.43K +12,000 New
LTFS
20
Ladenburg Thalmann Financial Services
Florida
$1K -$90 -447 -7%
Bank of America
21
Bank of America
North Carolina
$1K +$681 +3,365 +337%
KCPG
22
Kavar Capital Partners Group
Kansas
$1K +$911 +4,500 New
BCM
23
Bridgeway Capital Management
Texas
– -$44K -223,500 Closed
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
– -$25K -127,313 Closed
Bank of New York Mellon
25
Bank of New York Mellon
New York
– -$5K -27,317 Closed
1
2

GNMX Hedge Fund Activity: Q2 2019 in Review

29 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q2 2019, worth a combined $752K — down 6.4% from $803K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new GNMX positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 7 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $175K. The largest seller was Virtu Financial, cutting an estimated $46.9K.

  • 29 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q2 2019, up from 28 in Q1 2019.
  • Funds reported $752K of Aevi Genomic Medicine Inc stock for Q2 2019, down 6.4% quarter-over-quarter.
  • 4 funds opened new Aevi Genomic Medicine Inc positions in Q2 2019 and 3 closed out, a net change of +1 holder.
  • The largest Aevi Genomic Medicine Inc buyer in Q2 2019 was Renaissance Technologies, an estimated $175K added.
  • The largest Aevi Genomic Medicine Inc seller in Q2 2019 was Virtu Financial, an estimated $46.9K sold.

Based on aggregated 13F filings for Q2 2019.